XELOX for Metastatic Breast Cancer
Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.
Metastatic Breast Cancer
DRUG: Capecitabine and Oxaliplatin
Overall response rate
Toxicity|Time to progression
Both capecitabine and oxaliplatin have single agent activity in breast cancer. The combination has improved activity in other solid tumors. This study seeks to assess the activity of the combination in breast cancer.